BLUE BELL, Pa.--(BUSINESS WIRE)--Jan. 31, 2006--Locus Pharmaceuticals, Inc., a computationally-based drug design and development company, announced today that it has entered into a research agreement with Eli Lilly and Company (NYSE:LLY), whereby Locus will apply its proprietary computational technologies to design small molecule compounds having activity against a protein kinase target identified by Lilly. Financial and other terms of the agreement were not disclosed.
